Acute Leukemias IX: Basic Research, Experimental Approaches and Novel Therapies

by Hiddemann, W.; Haferlach, T.; Buchner, T.; Ritter, J.; Unterhalt, M.; Hiddemann, W.

• ISBN13: 9783540439714
• ISBN10: 3540439714
• Edition: 1st
• Format: Hardcover
• Copyright: 2003-04-01
• Publisher: Springer Verlag

Summary

Ludwig-Maximillians-Universitat, Muchen, Germany. Text provides an overview of the complex field of leukemia research. Covers basic research and clinical studies and emphasizes both aspects are equally necessary to achieve improvements in treating leukemias. For researchers and practitioners.

Table of Contents

Epidemiology and Classification
The New Who Classification for Acute Myeloid Leukemias and Myelodysplastic Syndromes	3	(4)
T. Haferlach
C. Schoch
W. Hiddemann
How Representative is the GMALL of the German Population?	7	(3)
D. Messerer
M. Dugas
T. Haferlach
B. Heinze
D. Hoelzer
H. Rieder
R. Schoch
S. Schwartz
C. Sperling
Philadelphia Chromosome-Positive Mature B-Cell (Burkitt Cell) Leukemia	10	(2)
G. Mann
O.A. Haas
E.R. Grumayer-Panzer
M.N. Dworzak
M.M. Trebo
H. Gadner
8-Years Experience of Ukrainian Reference Laboratory for Diagnosis of Acute Leukemias in Children	12	(3)
D Gluzman
L. Sklyarenko
V Nadgornaya
I. Abramenko
L. Poludnenko
S. Yaremenko
V. Drozdova
G. Klimnyuk
Establishment of the B-Cell Precursor-Acute Lymphoblastic Leukemia Cell Line MUTZ-5 Carrying a (12;13) Translocation	15	(6)
C. Meyer
R.A.F. MacLeod
H. Quentmeier
J.W.G. Janssen
L. Coignet
H.G. Drexler
Molecular Genetics, Transcription Factors and Signaling
The t(8;21), t(12;21), and inv(16) Fusion Proteins Contact Co-Repressors and Histone Deacetylase to Repress Transcription	21	(4)
S.W. Hiebert
B. Lutterbach
J. Amann
K. Durst
B. Linggi
Disturbed Differentiation of AML1/ETO Transduced Human CD34+ Progenitors	25	(3)
J. Basecke
Ch. Baum
O. Pfahlert
G. Brittinger
B. Wormann
F. Griesinger
Inducible AML1/ETO Expression in U-937 Myeloid Cells: A Model to Identify Genes Targeted by the Leukemia-Specific Fusion Protein	28	(6)
M. Fliegauf
J. Burger
R. Claus
M. Stock
F. Otto
M. Lubbert
Mix and Match Gene Fusions with TEL and AML1	34	(6)
A. Aloisi
M. Daniotti
G. Cazzaniga
A. Biondi
Transcriptional Repression of C/EBPα by Histone Deacetylases in Acute Myeloid Leukemia	40	(4)
B. Steffen
M. Ruthardt
K. Becker
S. Klumpen
M. Moller
W.E. Berdel
H. Serve
C. Muller-Tidow
Biology of Transcription Factor GATA-2 in Normal and Leukaemic Haematopoiesis	44	(8)
S. Tsuzuki
J. Brown
K. Gale
C. Heyworth
G. May
T. Enver
Retinoic Acid in Myeloid Differentiation and Acute Promyelocytic Leukemia (APL)	52	(10)
R.J. Lin
R.M. Evans
Combined Arsenic Trioxide and GM-CSF Induces Differentiation in Retinoic Acid (RA)-Sensitive as well as -Resistant APL Cells by Modulating Jak2 Kinase	62	(5)
M. Kizaki
A. Muto
Y. Ikeda
Different Mechanisms Lead to Rearrangements of the MLL Gene in Cases with Acute Myeloid Leukemia (AML) and Translocation t(10;11)	67	(5)
M. Klaus
S. Schnittger
T. Haferlach
M. Dreyling
W. Hiddemann
C. Schoch
Genes Specifically Expressed in Monocytic AML Cells Identified by Array Technology	72	(5)
P.A. Horn
H. Tesch
V. Diehl
D. Voliotis
Oncogenic Activation of Growth Factor Signals in AML	77	(7)
H. Serve
M. Mizuki
J. Schwable
C. Muller-Tidow
W.E. Berdel
Establishment of Inducible Expression Systems to Study the Role of STAT-Transcription Factors in AML	84	(6)
S. Franzrahe
T. Schroeder
U. Just
R. Balling
W. Hiddemann
K. Spiekermann
Farnesyltransferase Inhibitors in Leukemia	90	(7)
J.E. Lancet
J.D. Rosenblatt
J.E. Karp
Therapeutic Strategies that Overcome Resistance to Nucleoside Analogues: Dysregulating Checkpoint Response and Survival Pathways by UCN-01	97	(12)
Z. Shi
D. Sampath
W. Plunkett
Imatinib (ST1571) for the Treatment of Chronic Myelogenous Leukemia (CML)	109	(10)
A. Hochhaus
T. Lahaye
S. Kreil
U. Berger
P. Paschka
M.C. Muller
C. Kuhn
A. Weisser
K. Merx
R. Hehlmann
Leukemia Stem Cells
The Stem Cell Leukaemia Gene: A Critical Regulator of Haemopoiesis and Vasculogenesis	119	(3)
A.R. Green
Establishment of the Two Cytokine-Dependent Acute Myeloid Leukemia-Derived Cell Lines MUTZ-8 and MUTZ-11	122	(6)
Z.-B. Hu
H. Quentmeier
C. Meyer
R.A.F. MacLeod
H.G. Drexler
Leukemia Stem Cells with Efficient Drug Efflux in Acute Myeloid Leukemia	128	(8)
G.G. Wulf
R.-Y. Wang
M.K. Brenner
M. Andreeff
M.A. Goodell
Growth of Leukemic Progenitor Cells of Acute Lymphoblastic Leukemia in Co-Culture with Murine Stromal Cell Line MS-5	136	(17)
I.Jinnai
K. Nagai
Y. Kawaguchi
F. Yagasaki
Y. Yakata
T. Matsuo
K. Kuriyama
M. Tomonaga
Reduced Level of Philadelphia Chromosome Positive (Ph+) Cells in Lineage Negative Side Population Bone Marrow Progenitor Cells from Patients with Chronic Myeloid Leukemia (CML)	140
D.A. Weidner
R.-Y. Wang
S. Zhao
L. Calvert
I. Kuenle
H. Kantarjian
M.K. Brenner
M.A. Goodell
M. Andreeff
Developmental Therapeutics
New Developmental Agents and Directions in the Treatment of Acute Myelogenous Leukemia	153	(8)
B.D. Cheson
Investigational Therapy in Acute Myeloid Leukemia: 2001	161	(4)
E.J. Feldman
CMA-676: Mechanisms of Action and Clinical Results	165	(4)
R.A. Larson
Mylotarg Therapy in Acute Myeloid Leukemia: Mechanism of Action and Implications for Future Treatment Protocols	169	(8)
V.H.J. van der Velden
M.S. Berger
J.J.M. van Dongen
Antibody-Based Therapy of Myeloid Leukemia	177	(9)
J.G. Jurcic
Anti-angiogenic Therapy in Acute Myeloid Leukemia	186	(7)
R.M. Mesters
8-Chloro-cAMP Serves as a Prodrug for the RNA Directed Nucleoside Analog, 8-Chloro-Adenosine	193	(7)
Ch.M. Stellrecht
N. Krett
M. Ayres
S. Rosen
V. Gandhi
Pharmacokinetics and Pharmacodynamics of Daunoxome in Acute Myeloid Leukemia Patients	200	(5)
V. Isaev
V. Savchenko
T. Garmaeva
E. Parovitchnikova
A. Skorohod
A. Pivnic
F. Ataulakhanov
Drug Resistance, Apoptosis
Modulation of Multidrug Resistance in Acute Myeloid Leukemia	205	(8)
A.F. List
Proliferative Activity of Leukemic Blasts and Cytosine Arabinoside Pharmacodynamics are Associated with Cytogenetically Defined Prognostic Subgroups in Acute Myeloid Leukemia	213	(7)
J. Braess
G. Jahns-Streubel
C. Schoch
D. Haase
T. Haferlach
M. Fiegel
S. Voss
W. Kern
E. Schleyer
W. Hiddemann
No Evidence of MDR1 Gene Related Clonal Selection in Relapsed or Refractory Acute Myeloid Leukemia (AML)	220	(12)
M.M. v.d. Heuvel-Eibrink
E.A.C. Wiemer
M.J. de Boevere
B. van der Holt
P.J.M. Vossebeld
R. Pieters
P. Sonneveld
The Role of Mutations in the Deoxycytidine Kinase (dCK) Gene in the Development of Acute Myeloid Leukemia (AML) Towards Relapsed and/or Refractory Disease	232	(20)
M.M. van den Heuvel-Eibrink
E.A.C. Wiemer
M. Kuipers
R. Pieters
P. Sonneveld
Quantitative Determination of Bcl-2 Expression in AML Cell Lines and in Normal and Leukemic Progenitor Cell Compartments by Laser Scanning Cytometry: Comparison with Flow Cytometry and Western Blot	239
R.-Y. Wang
D Weidner
T. McQueen
J. McMannis
M. Korbling
R. Champlin
M. Andreeff
Apoptosis of Peripheral Blood Leukocytes in Children Survived from Acute Lymphoblastic Leukemia	252	(7)
E.B. Vladimirskaya
K.S. Kaznacheev
E.Yu. Osipova
T.A. Astrelina
S.A. Rumiantsev
In Vitro Sensitivity to Chemotherapy-Induced Apoptosis in CD2-positive and CD2-negative Childhood T-ALL	259	(4)
C. Wuchter
V. Ruppert
A. Mrozek
T. Hillebrand
P.T. Daniel
B. Dorken
W.-D. Ludwig
L. Karawajew
A Systematic Approach to the Dissection of Apoptotic Blockades in Treatment-Refractory Acute Myeloid Leukemias	263	(4)
P. Schneiderat
C. Schoch
K. Heil
I. Zimmerman
W. Hiddemann
J. Braess
GM-CSF is the Mediator of the Proliferative Effect of Tumor Necrosis Factor Alpha in Acute Myeloid Leukemia-Derived Cell Lines	267	(6)
H. Quentmeier
D. Fleckenstein
W.G. Dirks
C.C. Uphoff
M. Zaborski
H.G. Drexler
Acute Myeloid Leukemias Differ at Primary Diagnosis and Relapse in Endogenous Proliferative Activity, Response to Stimulation by Exogenous G-CSF and GM-CSF and Production of G-CSF	273	(4)
M. Fiegl
I. Zimmermann
K. Heil
C. Schoch
W. Kern
W. Hiddemann
J. Braess
Etoposide Induces Transition of 14-3-3 from the Cytoplasma into the Nucleus where it Binds to Topoisomerase II	277	(5)
T. Bartscht
M. Clark
D. Kroll
F. Gieseler
The CCC-Assay: A New Assay for Characterization of Leukaemic Cells Surviving Chemotherapy In-Vitro	282	(5)
T. Schinkothe
M. Gierling
A. Puppe
D. Voilotis
V. Diehl
P. Staib
Resistance to Drug-Induced Cytotoxicity in Acute Myeloid Leukemia is Significantly Correlated Between Inhibitors of Topoisomerase I and II and Nucleoside Analogues	287	(4)
I.Zimmermann
M. Fliegl
P. Schneiderat
C. Schoch
W. Kern
W. Hiddemann
J. Braess
Age-Related Differences in Cellular Drug Resistance in Children with Acute Myeloid Leukemia (AML)	291	(10)
Ch.M. Zwaan
G.J.L. Kaspers
R. Pieters
D.R. Huismans
U. Creutzig
K. Hahlen
E.R. van Wering
A.J.P. Veerman
Prognostic Factors, Minimal Residual Disease
FLT3 Length Mutations and MLL-Duplications in AML: Correlation to Cytogenetics, FAB-Subtype, and Prognosis	301	(5)
S. Schnittger
C. Schoch
M. Dugas
W. Kern
P. Staib
Ch. Wuchter
M. C. Sauerland
H. Serve
T. Buchner
T. Haferlach
W. Hiddemann
Identification of Partial Tandem Duplications of the MLL Gene in Acute Myeloid Leukemia: Prospective Analysis within the Multicenter Treatment Trial AML HD98-A	306	(6)
K. Tobis
R.F. Schlenk
C. Liebisch
S. Frohling
H. Dohner
K. Dohner
Single-Center Retrospective Analysis of Prognosis of 138 Patients Older than 55 Years with Acute Myeloid Leukemia	312	(9)
M. Lubbert
R. Kunzmann
C. Schmoor
D. Behringer
R. Mertelsmann
B. Behringer
Acute Myeloid Leukemia in Elderly Patients: Prognostic Value of Bone Marrow Aspirate on 14th Day of Induction Treatment	321	(6)
G. Specchia
F. Alabano
D. Pastore
P. Carluccio
C. Buquicchio
V. Liso
Simultaneous Monitoring of Minimal Residual Disease by RT-PCR of PML/RARα and RARα/PML Fusion Transcripts in Acute Promyelocytic Leukemia (APL)	327	(5)
S. Saussele
A. Weisser
A. Reichert
W. Seifarth
A. Hochhaus
T. Buchner
R. Hehlmann
E. Lengfelder
Cytogenetic Studies and Cell Cycle Parameters in Acute Lymphoblastic Leukemia (ALL) in Children	332	(6)
O. Haus
B. Mucha
A. Kurylak
K. Soszynska
R. Debski
M. Wysocki
Reliability of BCR-ABL RT-PCR in Adult B-Lineage Lymphoblastic Leukemia: Results of Confirmational PCR	338	(4)
B. Gleissner
C.R. Bartram
H. Rieder
L.A.J. Janssen
J.W.G. Janssen
N. Goekbuget
D. Hoelzer
C. Fonatsch
B. Heinze C. Schoch
E. Thiel
Evaluation of Minimal Residual Disease (MRD) in Children with T-Lineage Acute Lymphoblastic Leukemia	342	(4)
J. Peregud-Pogorzelski
J. Lubinski
A. Brodkiewicz
A. Jakubowska
R. Debski
M. Wysocki
Evaluation of Minimal Residual Disease (MRD) in Children with B-Cell Acute Lymphoblastic Leukemia During Maintenance of Remission	346	(4)
J. Peregud-Pogorzelski
J. Lubinski
A. Brodkiewicz
A. Jakubowska
V. Swiatkiewicz
A. Kurylak
Frequency of Cytogenetic Aberrations and their Influence on Results of Treatment in Childhood Acute Lymphoblastic Leukemia (ALL)	350	(5)
J. Peregud-Pogorzelski
S. Zajaczek
J. Lubinski
A. Brodkiewicz
M. Wysocki
A. Koltan
Evaluation of Minimal Residual Disease (MRD) in Children with B-Cell Acute Lymphoblastic Leukemia after Completion of Induction Therapy	355	(4)
J. Peregud-Pogorzelski
J. Lubinski
A. Brodkiewicz
A. Jakubowska
R. Debski
M. Wysocki
Evaluation of Minimal Residual Disease using PCR	359	(4)
A. Wypych
A. Raciborska
R. Rokicka-Milewska
J. Siedlecki
J. Kulik
Treatment of AML
Biology Based Treatment Strategies for Acute Myeloid Leukemia	363	(3)
W. Hiddemann
A. Heinecke
J. Braess
C. Schoch
T. Haferlach
W. Kern
T. Buchner
Cytogenetics for Treatment Stratification in de novo Adult Acute Myeloid Leukemia	366	(11)
C.D. Bloomfield
K.J. Archer
K. Mrozek
J.C. Byrd
S.P. Whitman
R.K. Dodge
A.J. Carroll
R.A. Larson
M.A. Caliguiri
Biology Oriented Investigation of Treatment Strategies for Acute Myeloid Leukemia (AML): The AMLCG Approach	377	(4)
T. Buchner
W. Hiddemann
W.E. Berdel
B. Wormann
C. Schoch
H. Loffler
T. Haferlach
P. Staib
A. Gruneisen
C. Aul
A. Giagounidis
A. Heyll
E. Lengfelder
W.-D. Ludwig
G. Maschmeyer
H. Rasche
H. Eimermacher
L. Balleisen
H.J. Pielken
H.E. Reis
F. Griesinger
A. Reichle
G. Schott
M.C. Sauerland
A. Heinecke
Therapy of Newly Diagnosed Acute Promyelocytic Leukemia. Results of the AMLCG	381	(4)
E. Lengfelder
R. Hehlmann
W. Hiddemann
T. Buchner
FS-HAI for Relapsed AML	385	(9)
W. Kern
A. Kerkhoff
A. Matylis
A. Gruneisen
C. Huber
B. Wormann
T. Buchner
J. Ohnesorge
W.-D. Ludwig
W. Hiddemann
Treatment of AML and High-Risk MDS at M.D. Anderson: The Lone Star Approach	394	(10)
E. Estey
F. Giles
J. Cortes
M. Beran
C. Koller
S. O'Brien
S. Pierce
H. Kantarjian
Long Remissions after Late Relapse of Acute Myeloid Leukaemia (AML) with Idarubicin + Cytarabine Conventional Doses Treatment	404	(3)
A.Sokolov
E. Parovitchnikova
V. Isaev
S. Kulikov
V. Savchenko
Outcome of Patients with Refractory/Recurrent Acute Myelogenous Leukaemia (AML) Treated at a Single Centre	407	(5)
K. Scatchard
A.Z.S. Rohatiner
S. Slater
M. Camball Paralles
C. Davis
J. Amess
T.A. Lister
Phase I Clinical Evaluation of Topotecan Combined with Idarubicin and Cytarabine in Patients with Refractory or Relapsed Acute Myeloid Leukemia	412	(6)
X. Thomas
A. Belhabri
A. Thiebaut
Y. Chelghoum
M. Elhamri
D. Fiere
7+3+VP-16 as Remission Induction/Consolidation and Two Types of Maintenance in Adult AML: 8 Years Results of Russian Multicenter Trial	418	(5)
V.G. Savchenko
E.N. Parovitchnikova
V. Isaev
S. Kulikov
E.R. Maslova
L.S. Lubimova
L.P. Mendeleeva
E.O. Gribanova
E.N. Ustinova
L.Yu. Tihonova
T.S. Konstantinova
V.A. Lapin
L.B. Filatov
V.V. Cherepanova
E.A. Belousov
V.A. Tumakov
G.B. Rehtman
N.N. Klimko
E.V. Yarikova
L.N. Jeltukhina
V.A. Rossiev
A.S. Pristupa
T.S. Kaporskaya
M.A. Volkova
N.A. Obidina
T.I. Pospelova
N.V. Medvedeva
Interferon-α plus ATRA Maintenance in High Risk AML	423	(3)
E Parovitchnikova
V. Savchenko
I. Demidova
Yu. Olshanskaya
V. Isaev
V. Cherepanova
G. Rethman
V Lapin
T. Perekatova
Weekly Oral Idarubicin: An Ambulatory Treatment of Acute Myeloid Leukemia in Poor-Risk Elderly Patients	426	(5)
B. Anglaret
J. Troncy
Y. Chelghoum
M.C. Perrin
P. Renaudier
A. Belhabri
B. Corront
X. Thomas
Treatment of Relapsed AML of Childhood with Daunoxome-FLAG (Liposomal Daunorubicin, Fludarabine, High-Dose Cytarabine and G-CSF)	431	(10)
G. Fleischhack
N. Graf
C. Hasan
U. Bode
Treatment of ALL
ALL HRG-Experience with Modified New York Regimen	441	(4)
A. Krauze
M. Matysiak
Prospective, Multicenter Study of CNS-Toxicity and Health-Related Quality of Life in ALL-Patients	445	(6)
T. Langer
K. Zepf
P. Krappmann
Ch. Gravou-Apostolatou
J.D. Beck
Limited Success with a Postremission Strategy Comprising Conventional Consolidation and High-Dose Treatment (HDT) with Autologous Peripheral Progenitor Cell (PBPC) Support for Adult Acute Lymphoblastic Leukaemia (ALL)	451	(5)
R. Bassan
E. Di Bona
A. Rohatiner
E. Pogliani
G. Rossi
A. Porcellini
P. Fabris
G Lambertenghi-Deliliers
T. Lerede
A. D'Emilio
A. Rambaldi
T.A. Lister
T. Barbui
Single High-Dose Idarubicin in Advanced Acute Lymphoblastic Leukaemia: Clinical and Pharmacokinetics Results	456	(5)
M. Montillo
E. Strocchi
A. Tedeschi
L. Intropido
A.M. Cafro
A. Benini
C.M. Camaggi
E. Morra
Salvage Therapy for Resistant or Relapsing Acute Lymphoblastic Leukemia (ALL) after Idarubicin-Based Induction	461	(12)
E. Di Bona
R. Sartori
T. Lerede
G. Rossi
M. Vespignani
F. Rodeghiero
T. Barbui
R. Bassan
Transplantation and Cellular Immune Therapy
Transplantation Strategies for High Risk Acute Myeloid Leukemias	469
E. Holler
J. Hahn
M. Zaiss
A. Reichle
R. Andreesen
Current Role of Allogeneic and Autologous Hematopoietic Stem Cell Transplantation in Patients with AML	473	(6)
M. Bornhauser
U. Schaekel
M. Schaich
S. Soucek
G. Ehninger
Allogeneic Hematopoietic Stem Cell Transplantation with a Nonmyeloablative Conditioning Regimen	479	(4)
R.A. Nash
D. Niederwieser
P.A. MacSweeney
B.M. Sandmaier
G. Georges
D.G. Maloney
L. Feinstein
M. Maris
A Woolfrey
Th. Chauncey
J.M. Zaucha
K.G. Blume
J. Shizuru
R. Storb
Non-Myeloablative Stem Cell Transplantation for Acute Myelogenous Leukemia	483	(2)
T. Martin
S. Giralt
I. Khouri
R. Champlin
Adoptive Immunotherapy in Chimeras - Donor Lymphocyte Transfusions for the Treatment of Acute Myeloid Leukemia	485	(6)
H.-J. Kolb
Ch. Schmid
A. Woiciechowsky
M. Schleuning
O. Stoetzer
C. Schoch
G. Ledderose
Herpes Simplex Virus Thymidine Kinase-Transduced Human T Lymphocytes	491	(6)
S.B. Ebeling
E.R. Simonetti
M.I. Garin
K.F. Gaiser
Ch. Ferrand
J.F. Apperley
D. Chalmers
A. Hagenbeek
Interferon Alpha and Gamma Differentially Alter the Susceptibility of Tumor Cells to Lysis by MHC-Restricted and Non-MHC-Restricted Cytotoxic Effector Cells	497	(7)
E. Noessner
C.S. Falk
D.J. Schendel
Targeting Acute Leukemia and Cancer by High-Affinity T-Cell-Receptor Transfer	504	(4)
M. Theobald
R.-H. Voss
F. Schmitz
J. Kuball
C. Lotz
Nonmyeloablative Conditioning Regimen in Patients with High-Risk Acute Myeloid Leukemia: Unrelated and Sibling Allogeneic Hematopoietic Stem Cell Transplantation	508	(6)
N. Basara
E. Roemer
S. Guenzelmann
L. Kraut
B. Schmetzer
C. Seidl
E. Seifried
A.A. Fauser
M.G. Kiehl
Induction of Mixed Chimerism in Patients after Non-Myeloablative Stem Cell Transplantation (SCT) for High-Risk Haematological Malignancies	514	(6)
I.A. Demidova
Y.V. Olshanskaia
L.P. Poreshina
A.V. Misiurin
E.V. Lisovskaia
V.L. Surin
E.N. Parovitchnikova
V.G. Savchenko
Allogeneic Stem Cell Transplantation (SCT) with Reduced Intensity Conditioning (RIC) Immediately after Intensive Cytoreduction for High-Risk Myeloid Leukemias	520	(5)
M. Schleuning
C. Schmid
O. Stotzer
G. Ledderose
H.-J. Kolb
Allogeneic Stem Cell Transplantation (HSCT) for Secondary Acute Leukemia Following MDS	525	(5)
R Schwerdtfeger
S. Brauninger
M. Prumbaum
C. Kreissig
D. Judith
H. Mehdikhani
J. Weihrauch
S. Tonndorf
A. Burchardt
A. Yaman
C.-N. Klunder
H. Baurmann
Biology of Stem Cell Mobilization Induced by Cytokines	530	(3)
W. E. Fibbe
J. F.M. Pruijt
R. Willemze
Feasibility of High Dose Melphalan (140 mg/m2) and Peripheral Blood Stem Cell Support as Consolidation for Patients over 60 Years with Acute Myeloid Leukemia in First Complete Remission	533	(8)
A.-M. Stoppa
C. Faucher
N. Vey
R. Bouabdallah
C. Chabannon
P. Ladaique
G. Novakovitch
T. Aurran
A. Charbonnier
D. Coso
D. Sainty
M. Lafage
R. Costello
D. Blaise
J.-A. Gastaut
D. Maraninchi
Opportunistic Infections
Strategies for Empiric Antifungal Therapy in Neutropenic Patients	541	(6)
G. Silling
Acute Leukemias: Management of Infections	547	(7)
G. Maschmeyer
Leukopenia is no Risk Factor for Phlebitis Associated with Peripheral Teflon Catheters	554	(6)
U. Bethe
D. Waldschmidt
O.A. Cornely
PCR-Mediated Detection of Aspergillus Species in Bronchoalveolar Lavage Samples of Febrile Neutropenic Patients with Acute Leukemias: Clinical Results	560	(4)
D. Buchheidt
C. Baust
H. Skladny
M. Baldus
S. Brauninger
R. Hehlmann
Interleukin-8, Interleukin-6 and C-Reactive Protein Serum Concentrations in Acute Leukemia Patients without and with Clinical Symptoms of Infection	564	(7)
J. Nowicka
J. Milczarska
Supportive Care and Quality of Life
Update on Antiemetic Strategies	571	(7)
F. Roila
Quality of Life and Coping in Patients with Acute Myeloid Leukemia (AML)	578	(7)
A. Schumacher
D. Wewers
T. Buchner
W.E. Berdel
Helping Patients Deal with Sexual Difficulties During and after Cancer Treatment	585	(5)
U. Gruber
S.B. Weber
W. Hiddemann
Sperm Quality May be Impaired in Long-Term Acute Myeloid Leukemia Survivors after Chemotherapy	590	(3)
P. Lemez
V. Urbanek
Subject Index	593